Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
-FB-102 Has Demonstrated Potentially Best in Class Activity including Superiority to Standard of Care in GvHD -Proof of Concept Pre-clinical Data in Additional Indications with Large Market Potential...